| __timestamp | Merck & Co., Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7180000000 | 1271353000 |
| Thursday, January 1, 2015 | 6704000000 | 1620577000 |
| Friday, January 1, 2016 | 7194000000 | 2052295000 |
| Sunday, January 1, 2017 | 9982000000 | 2075142000 |
| Monday, January 1, 2018 | 9752000000 | 2186100000 |
| Tuesday, January 1, 2019 | 9872000000 | 3036600000 |
| Wednesday, January 1, 2020 | 13397000000 | 2735000000 |
| Friday, January 1, 2021 | 12245000000 | 2908100000 |
| Saturday, January 1, 2022 | 13548000000 | 3592500000 |
| Sunday, January 1, 2023 | 30531000000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Merck's R&D expenses surged by over 300%, peaking at an impressive $30.5 billion in 2023. This reflects Merck's aggressive pursuit of groundbreaking therapies. In contrast, Regeneron's R&D spending grew steadily, reaching $4.4 billion in 2023, marking a 250% increase since 2014. This strategic allocation underscores Regeneron's focus on targeted innovation. The data reveals a fascinating narrative of how these industry leaders prioritize their resources to drive future growth and maintain their competitive edge. As the pharmaceutical industry continues to evolve, these insights offer a glimpse into the strategic decisions shaping the future of healthcare.
R&D Insights: How Merck & Co., Inc. and argenx SE Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Merck & Co., Inc. and Ascendis Pharma A/S
Merck & Co., Inc. or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs Pharming Group N.V.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Veracyte, Inc.
Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.